Registry for Epithelioid Hemangioendothelioma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This registry collects high-quality prospective data on patients diagnosed with epithelioid hemangioendothelioma (EHE), an ultra-rare sarcoma. The study aims to improve understanding of the disease's natural history, identify prognostic factors, and evaluate treatment patterns and efficacy. It includes only new cases confirmed by expert pathologists and focuses on gathering comprehensive clinical data to address existing knowledge gaps. The registry is part of the European Reference Network on Rare Adult Solid Cancers (EURACAN).

Why it matters

Who can join: the full rules

Inclusion Criteria:

* New patients managed by the contributing centers with a pathological EHE diagnosis performed or verified by an expert sarcoma pathologist starting from 1 December 2023 onwards and to be performed within 6 months from the registration
* Molecular confirmation of the diagnosis (WWTR1-CAMTA1 or YAP1-TFE3)
* Adult patients (aged ≥ 18 years)

Where it's running

• University Hospital Graz
  Graz, Graz, Austria Recruiting
• Aarhus University Hospital
  Aarhus, Aarhus, Denmark Recruiting
• Léon Bérard Center
  Lyon, Lyon, France Recruiting
• Essen University Hospital
  Essen, Hesse, Germany Recruiting
• Istituto Ortopedico Rizzoli
  Bologna, Bologna, Italy Recruiting
• Azienda Ospedaliero Universitaria Careggi
  Careggi, Firenze, Italy Recruiting

Study contacts

• Study coordinator: Annalisa Trama, MD
• Email: annalisa.trama@istitutotumori.mi.it
• Phone: 02 2390 3535

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Preventing heart problems in overweight/obese young sarcoma survivors with tirzepatide

  This feasibility study tests whether tirzepatide can be safely given to overweight or obese young adults (18–39) who have completed doxorubicin for soft tissue or bone sarcoma to see if it’s feasible to use in the first year after therapy.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07874828

• Personalized PULSAR radiotherapy for advanced small cell lung cancer and brain metastases

  This trial will try personalized PULSAR radiotherapy schedules to see if they are safe and helpful for adults with extensive-stage small cell lung cancer who need thoracic radiation and for adults with 1–5 brain metastases.

  Recruiting Phase 1 University of Texas Southwestern Medical Center · Dallas, Texas · NCT07139990

• Sequential CD146- and HER2-targeted CAR T-cell therapy for advanced sarcoma

  This treatment will test whether giving a patient's own CAR T cells that target CD146 and HER2, one after the other, can shrink tumors in children and adults with relapsed or refractory advanced sarcoma.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07066982

• Preventing wound complications after limb sarcoma surgery with a single-use negative-pressure dressing

  This test will try a single-use negative-pressure wound dressing (PICO14) to see if it reduces wound complications after limb high-grade soft tissue sarcoma surgery in adults who received preoperative radiotherapy.

  Recruiting Istituto Oncologico Veneto IRCCS · Padova, Italy/Padova · NCT06941194

• Total pre-surgery chemotherapy plus regional hyperthermia for high-risk limb and trunk soft tissue sarcoma (TNT-HYPE)

  This trial will test whether giving three cycles of chemotherapy with regional hyperthermia before radiation and surgery is feasible and tolerable for people with high-risk soft tissue sarcoma of the arms, legs, or trunk.

  Recruiting at 8 sites Phase 2 Swiss Cancer Institute · Aarau and 7 other locations · NCT06835049

• Comparing a new treatment to standard care for adults with advanced soft tissue sarcomas

  This study is testing a new treatment called INT230-6 to see if it helps adults with advanced soft tissue sarcomas live longer compared to the usual care they receive.

  Recruiting at 17 sites Phase 3 Intensity Therapeutics, Inc. · Los Angeles, California and 16 other locations · NCT06263231

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.